Can you have a regulatory strategy in place to accelerate drug development — without getting slowed down by compliance considerations?
The COVID-19 pandemic has created an inflection point between the need for speed and the need to protect patient safety. For this balancing act to succeed, drug developers need a detailed, forward-thinking regulatory strategy. With a strategy in place — and expert guidance to help put it into action — you will be able to improve response time in the face of unexpected health crises.
The lessons we learn today will reshape the pharma industry’s capability to respond more quickly and more safely. Building compliance strategy into ongoing operations will be essential to maximizing that capability. There are three components to a rapid, compliant response...
Read the rest of this article from our sister publication Pharma Manufacturing.
_Software.png?auto=format,compress&fit=crop&h=139&w=250&q=45)
